AN2 Therapeutics has discontinued its mid to late-stage study on epetraborole for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease due to unsatisfactory efficacy results. The company is now focusing on restructuring and exploring other potential uses for epetraborole. AN2 Therapeutics is also moving forward with clinical trials for its other drug candidates.